comparemela.com

Latest Breaking News On - Magenta therapeutics company profile - Page 1 : comparemela.com

Magenta Therapeutics (NASDAQ:MGTA) Shares to Split on Thursday, September 7th

Shares of Magenta Therapeutics, Inc. (NASDAQ:MGTA – Free Report) are going to split on the morning of Thursday, September 7th. The 2-1 split was announced on Thursday, September 7th. The newly created shares will be issued to shareholders after the market closes on Thursday, September 7th. Magenta Therapeutics Price Performance Magenta Therapeutics stock opened at […]

Short Interest in Magenta Therapeutics, Inc (NASDAQ:MGTA) Rises By 21 2%

Magenta Therapeutics, Inc. (NASDAQ:MGTA – Get Rating) was the recipient of a large increase in short interest in May. As of May 31st, there was short interest totalling 495,600 shares, an increase of 21.2% from the May 15th total of 408,800 shares. Based on an average daily volume of 504,400 shares, the days-to-cover ratio is […]

Inspire Corporate Bond ETF Announces Dividend of $0 07 (NYSEARCA:IBD)

Magenta Therapeutics, Inc. (NASDAQ:MGTA – Get Rating) was the target of a significant drop in short interest in the month of May. As of May 15th, there was short interest totalling 408,800 shares, a drop of 56.0% from the April 30th total of 930,000 shares. Based on an average trading volume of 514,400 shares, the […]

Magenta Therapeutics, Inc (NASDAQ:MGTA) Expected to Post Q2 2023 Earnings of ($0 19) Per Share

Magenta Therapeutics, Inc. (NASDAQ:MGTA – Get Rating) – Stock analysts at Wedbush boosted their Q2 2023 earnings per share (EPS) estimates for Magenta Therapeutics in a research report issued on Tuesday, May 16th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($0.19) for the quarter, up from their […]

Magenta Therapeutics, Inc (NASDAQ:MGTA) Given Average Rating of Hold by Brokerages

Shares of Magenta Therapeutics, Inc. (NASDAQ:MGTA – Get Rating) have received a consensus recommendation of “Hold” from the six brokerages that are currently covering the stock, Marketbeat reports. Five research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 12-month price objective among […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.